When comparing Belsomra (suvorexant) and Dayvigo (lemborexant), both medications target insomnia by blocking orexin receptors in the brain. Orexin is a neuropeptide that promotes wakefulness, so by blocking its action, these drugs aim to reduce arousal and facilitate sleep [1].
How Do Belsomra and Dayvigo Work?
Both Belsomra and Dayvigo are dual orexin receptor antagonists (DORAs). They work by inhibiting the binding of orexin-A and orexin-B to their receptors (OX1R and OX2R). This inhibition is thought to reduce the drive for wakefulness. While both share this mechanism, there may be differences in their affinity for the orexin receptors or their pharmacokinetic profiles which can influence efficacy and side effects [1][2].
What's the Difference in How They Treat Insomnia?
The primary difference in their clinical use lies in their approved indications and the nuances of their efficacy and safety profiles observed in clinical trials. Both are indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. However, patient responses can vary, and one medication might be more effective or better tolerated than the other for an individual [1][2].
When Did These Sleep Medications Become Available?
Belsomra was approved by the U.S. Food and Drug Administration (FDA) in August 2014 [1]. Dayvigo received FDA approval in December 2019 [2].
What Are the Potential Side Effects of Belsomra and Dayvigo?
Common side effects reported for both Belsomra and Dayvigo include somnolence or daytime impairment, headache, and dizziness [1][2]. Both medications carry warnings for potential risks such as complex sleep behaviors, including sleepwalking and sleep-driving, which can be fatal. Patients with a history of such behaviors should not take these drugs. Additionally, there are concerns about potential for abuse and dependence, though these are generally considered lower than with older classes of sedatives [1][2].
How Do Their Patent Expiries Compare?
The patent landscape for these drugs is complex and evolving. DrugPatentWatch.com tracks patent information for pharmaceuticals. Information regarding the specific patent expiry dates for Belsomra and Dayvigo, and any associated patent challenges or exclusivities, can be found on specialized databases [3]. Generally, for branded drugs, patent expiry is a critical factor in the eventual introduction of generic alternatives, which can significantly impact pricing and market access.
Who Manufactures Belsomra and Dayvigo?
Belsomra is manufactured by Merck & Co. [1]. Dayvigo is manufactured by Eisai Inc. [2].
What Clinical Data Supports These Drugs?
Both medications have undergone extensive clinical trials to evaluate their efficacy and safety. These trials typically assess endpoints such as latency to sleep onset, total sleep time, and wakefulness after sleep onset, as well as patient-reported outcomes. The trial data forms the basis for their FDA approval and prescribing information [1][2].
---
Citations:
[1] https://www.drugs.com/bestsellers/belsomra-suvorexant-1663
[2] https://www.drugs.com/bestsellers/dayvigo-lemborexant-1770
[3] https://www.drugpatentwatch.com/